IRVINE, Calif., June 21, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces a new peer-reviewed study demonstrating that treatment decisions informed by Proove Opioid Risk® result in better patient outcomes and positive physician impact. This study, entitled "Prospective, Longitudinal Study to Evaluate the Clinical Utility of a Predictive Algorithm to Detect Opioid Use Disorder in Chronic Pain Patients" has been accepted for publication by the Journal of Addiction Research & Therapy (Impact factor 1.4).
Researcher Katrina Lewis, M.D. of Benefis Healthcare System's Pain Medicine department teamed with Proove® scientists to conduct a multi-center, prospective study across 76 clinics involving 5,315 patients to determine the clinical utility of an algorithm-based precision medicine profile to assess risk for opioid use disorder (OUD). Building on three peer-reviewed clinical validity studies showing stable predictive accuracy up to 96.7%, and dozens of published studies showing that the 17 component factors of this technology correlate with opioid risk behaviors, this new study evaluated whether Proove Opioid Risk® impacts physician decision-making and, if so, do patients get better.
Results show that when clinicians use Proove Opioid Risk®, patients experience less pain without opioid abuse. 91% of patients reported pain reduction after receiving care guided by Proove Opioid Risk®. The average pain reduction was 42%, or a reduction from 6.7 to 3.9 on a 0 to 10 numerical rating scale (p= 5.27 x 10-152). Almost 40% of patients had more than a 50% reduction in pain, and 13% reported complete elimination of pain.
At least 90% of physicians stated Proove Opioid Risk® benefited their patients, with 27% indicating "significant benefit." Those benefits included: opioid discontinuation (p=1.17 x 10-6), advised another provider (p=3.16 x 10-3), confidence in medical regimen p=1.81 x 10-15), and changed opioid or dosage (p=1.39 x 10-6).
Dr. Ashley Brenton, Director of R&D at Proove® explains, "With many tools and technologies available to clinicians, patients, and payers, this study demonstrates that Proove Opioid Risk® is clinically superior. It not only avoids opioid abuse, but also helps physicians make better decisions to reduce patient pain and support more rational opioid utilization, such as reducing utilization in high risk populations."
About Proove® Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals. Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/large-peer-reviewed-prospective-outcomes-study-of-proove-opioid-risk-shows-positive-patient-benefits-and-strong-physician-ratings-300477195.html
SOURCE Proove Biosciences, Inc.